Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leverages Research to Promote Mental Health

  • Delic Holdings Corp, a leader in new medicines and treatments for a modern world, understands that research is integral for both the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for the treatment of mental health issues
  • Dr. Markus Roggen, President and CSO of Delic Labs, recently spoke at this year’s Emerald Conference, and has reiterated the importance of leveraging AI in crafting products for the cannabis industry
  • Delic is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products for more people, supporting mental health while building shareholder value

Since its inception, Delic Holdings (CSE: DELC) (OTCQB: DELCF) has remained committed to emphasizing the value of research and education in support of mental health. In addition, it has helped drive the reframing of the psychedelic conversation while being at the forefront of the ongoing psychedelics renaissance. 

Delic understands that research is integral if psychedelics are to be widely adopted for treating mental issues. This is further reinforced by Delic Labs, a wholly-owned subsidiary of Delic and the only licensed entity exclusively focused on research and the development of psilocybin vaporization technology in Canada.

Psilocybin has proven to be an effective treatment for depression, a condition affecting 50% of Americans today, and has received approval from the United States Food and Drug Administration (“FDA”). 

The FDA has also approved esketamine, a fast-acting antidepressant that can reduce suicide rates which currently stand at one suicide every 40 seconds. Additionally, psilocybin has also proven useful and effective for smoking cessation, an issue that affects over 50 million people in the United States (

Delic’s focus on research is moving society closer to the full adoption of psychedelics for the treatment of mental health issues by pushing the narrative regarding psychedelics, their usefulness, and their potential, even beyond mental health treatment. In addition, Delic is also expanding the boundaries of how such research is conducted, particularly given its current use of Artificial Intelligence (“AI”) for crafting products for the cannabis industry.

Dr. Markus Roggen, the President and Chief Science Officer (“CSO”) of Delic Labs, recently spoke at this year’s Emerald Conference held February 2022, in San Diego. Known for providing a platform for scientific communication and collaboration, this conference was an excellent avenue for Delic to share its progress and standing on psychedelics and cannabis research. Of note was Dr. Roggen’s emphasis on the importance of why leveraging AI can help increase the quality of the extract while keeping overhead at an all-time low (

“Focusing solely on extraction yields for cannabis extraction operations is an imprecise way to think about production,” noted Dr. Roggen.

“Quality of extract, cost of extraction, and loss in post-processing should all be considered. Our laboratory undertook extensive experimental studies on the extraction behavior of various solvents, and we’re excited to present our latest results and insights from developing and utilizing our extraction optimization AI,” he added.

Dr. Roggen’s research into process optimization and analytical methods has earned him several awards, including the ElSohly Award of the ACS, the 40 under 40 by Marijuana Venture Magazine, as well as the Cannabis Scientist Power List 2020 & 2021. His leadership of Delic Labs represents what Delic Holdings stands for, the value that it sees in R&D, and the potential that psychedelics hold for mental health treatment.

Delic is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products for the masses. By doing so, the company generates shareholder value as well as effective solutions for those struggling with mental health issues.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050